Saturday 17 October 2026 Export ARQT’s income statement to Excel — free account

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

28.82 0.28 −0.96%

Follow ARQT

Alert me

Market cap: $3.7B
P/E: 131×
Fwd P/E: 196×
Dividend yield: —
F-score: 4/9
Altman Z: 6.98
Beneish M: −1.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 14.95

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	12	4	2	7	6	1	7	2	1	8	2	—

Insider Ownership 16.10%

Capital & Financial Ratios $m

Market Cap 3,660.00

Revenue 463.98

Net Income 28.52

Free Cash Flow 39.07

Net Debt (129.96)

Current Ratio 2.92

Debt/Equity 0.49

P/E ratio 131.00

Fwd P/E 196.00

P/S ratio 8.11

P/B ratio 17.05

Past 5Y EPS Growth —

This Y EPS Growth 473.08%

Next Y EPS Growth 159.54%

Next Y revenue growth 42.98%

Next 5Y EPS Growth 9.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 43.12%

10-year low 10-year high

P/B against its own 10 years 94.05%

10-year low 10-year high

EV/Sales against its own 10 years 48.91%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	273	229	221	239
Receivables	26	73	146	155
Inventory	13	15	23	39
Other	—	—	—	—
	330	336	411	468

	2023	2024	2025	Q'26
Payables	12	14	13	7
ST’ Debt	—	—	1	7
Other	—	—	—	—
	47	81	130	160

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	367.27%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(6.88%)	(3.31%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	105	130	—	—	—
’25	66	82	99	130	376
’24	50	31	45	71	197
’23	3	5	38	14	60

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	13	—	—	—
’25	(30)	0	(2)	26	(6)
’24	(32)	(45)	(35)	(1)	(112)
’23	(80)	(66)	(44)	(56)	(247)
’22	(57)	(62)	(68)	(71)	(258)
’21	(46)	(36)	(41)	(52)	(175)
’20	(21)	(26)	(34)	(33)	(113)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	12	—	—	—
’25	(31)	(10)	(2)	26	(16)
’24	(32)	(45)	(35)	(6)	(117)
’23	(80)	(67)	(44)	(56)	(247)
’22	(57)	(62)	(91)	(71)	(281)
’21	(47)	(36)	(41)	(52)	(176)
’20	(21)	(26)	(34)	(33)	(113)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	0.11	—	—	—
’25	(0.20)	(0.13)	0.06	0.13	(0.13)
’24	(0.32)	(0.42)	(0.33)	(0.09)	(1.16)
’23	(1.31)	(1.16)	(0.73)	(0.72)	(3.78)
’22	(1.27)	(1.31)	(1.89)	(1.18)	(5.66)
’21	(0.76)	(0.84)	(1.14)	(1.42)	(4.18)
’20	(1.15)	(0.94)	(1.01)	(0.79)	(3.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	17.10	14.16	13.37	1.76	3.07	11.13	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	40.88	38.49	27.40	17.57	15.79	31.77
People
People	Employees	—	—	29	29	54	147	268	296	342	354
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.01	0.20	0.57	1.06
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	4	60	197	376
	Gross margin, %	—	—	—	0.00	0.00	0.00	79.54	91.63	90.27	90.24
	EBT	—	(5)	(19)	(42)	(136)	(206)	(311)	(259)	(139)	(15)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	(8,449.76)	(434.57)	(70.92)	(3.98)
	Net income	—	(5)	(19)	(42)	(136)	(206)	(311)	(262)	(140)	(16)
	Depreciation	—	—	0	0	0	4	(1)	(6)	(5)	3
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.07	0.86	1.62	2.96
	Earnings	—	(7.16)	(15.53)	(22.78)	(3.80)	(4.18)	(5.66)	(3.78)	(1.16)	(0.13)
	Cash flow	—	(5.43)	(11.36)	(23.24)	(3.17)	(3.53)	(4.68)	(3.56)	(0.93)	(0.04)
	Capex	—	0.00	0.00	(0.16)	(0.01)	(0.02)	(0.42)	(0.01)	(0.04)	(0.08)
	Free cash flow	—	(5.43)	(11.36)	(23.40)	(3.18)	(3.55)	(5.11)	(3.57)	(0.97)	(0.13)
	Book value	—	0.00	(19.35)	(35.28)	7.59	6.03	3.81	1.28	1.30	1.49
	Shares, m	—	1	1	2	36	49	55	69	121	127
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	0.00	3.99	8.57	9.82
	P/B	—	—	—	—	—	—	3.88	2.68	10.70	19.50
	EV/Sales	—	—	—	—	—	—	0.00	2.81	8.46	9.53
	EV/FCF	—	—	—	—	—	—	(2.20)	(0.68)	(13.32)	(168.11)
Cash, $m
Cash, $m	Operating cash flow	—	(4)	(14)	(43)	(113)	(175)	(258)	(247)	(112)	(6)
	Capex	—	—	—	0	0	(1)	(23)	0	(5)	(11)
	Free cash flow	—	(4)	(14)	(43)	(113)	(176)	(281)	(247)	(117)	(16)
Balance, $m
Balance, $m	Working capital	—	3	48	101	270	369	400	284	255	281
	Total debt	—	—	—	0	5	73	198	202	107	109
	Net debt	—	(3)	(51)	(101)	(281)	(316)	(212)	(71)	(121)	(112)
	Shareholders’ equity	—	—	(24)	(65)	271	298	210	89	158	189
Returns, %
Returns, %	ROA	—	(18.13)	(75.36)	(53.12)	(66.96)	(58.42)	(72.65)	(66.31)	(40.58)	(4.13)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	(852.31)	(221.85)	(9.91)
	ROE	—	34.35	132.88	94.36	(131.99)	(72.62)	(122.80)	(175.79)	(113.76)	(9.30)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LEGN Legend Biotech Corporation Sponsored ADR	$3.8B	— (loss-making)	112×	+51.90% (above 0%: growing)	n/m	−26.79% (below 0%: shrinking)	64.54%	14.37%	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
VKTX Viking Therapeutics, Inc.	$3.5B	— (loss-making)	—	—	n/m	−165.98% (below 0%: shrinking)	0.00%	0.00%	Compare
ACAD ACADIA Pharmaceuticals Inc.	$3.4B	8.5×	55.6×	+16.40% (above 0%: growing)	+12.50% (above 0%: growing)	+50.32% (above 0%: growing)	90.81%	12.29%	Compare
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$3.6B	—	—	+34.15%	—	−15.69%	90.81%	0.00%

All 614 Biotechnology stocks →

Arcutis Biotherapeutics, Inc. (ARQT) key facts

Strength: Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ARQT traded at $28.82, a market capitalization of $3.7 billion.
Return on equity was −9.30% and debt-to-equity 0.49.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 6.98 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.